Abstract: The present invention describes the action of a new family of drugs against a number of Leishmania species and Trypanosona cruzi, for the treatment of cutaneous, mucocutaneous and visceral leishmaniosis as well as tripanosomosis. In vitro assays and studies conducted in animal models and in human patients demonstrated that the compounds had a higher activity compared to drugs in clinical use against Leishmania mexicana amazonensis, L. donovani infantum, L. braziliensis braziliensis and Trypanosoma cruzi. The pharmaceutical activity of compositions based on such family of compounds was evidenced and supports its human and veterinary application for the treatment of the above-mentioned diseases by using different administration routes.

Abstract: The invention relates to the field of immunology and, more specifically, to the treatment of infectious diseases caused by mycobacteria, whereby antibody compositions are administered mucosally and in other ways for the prophylactic and therapeutic treatment of said diseases. The invention relates to the preparation of compositions of human antibodies of class IgG, secretory IgA or mixtures of both having a specific activity against mycobacterial antigens for the prevention and treatment of infections caused by said type of micro-organism. The inventive compositions have demonstrated their ability to prevent in vivo mycobacterial infection.